I
ntercellular adhesion molecule-1 (ICAM-1) is a cell-surface glycoprotein with five extracellular Ig-like domains (domains 1-5, D1-5), a hydrophobic transmembrane domain, and a short cytoplasmic domain. ICAM-1 is an inducible ligand for at least two members of the ␤2 family of leukocyte integrins, lymphocyte function-associated antigen-1 (LFA-1) (␣L␤2) and Mac-1 (␣M␤2) (1) (2) (3) , and is important for granulocyte extravasation (4) (5) (6) (7) (8) , lymphocyte-mediated cytotoxicity (9, 10) , and the development of specific immunologic responses involving cell-cell interactions (6, 7, 11, 12) . Antibodies to ICAM-1 inhibit leukocyte adhesion to endothelial cells, granulocyte migration through endothelium, mitogen-and Ag-induced lymphocyte proliferation, and mixed lymphocyte reactions (4, 5, 13, 14) . Furthermore, crosslinking of ICAM-1 activates signaling pathways in monocytes and endothelial cells (15, 16) . Given the potential clinical importance of ICAM-1͞LFA-1-mediated adhesion (17) , it is important to understand this receptor-ligand interaction at a fundamental level.
Integrins are large heterodimeric membrane glycoproteins composed of combinations of various ␣ and ␤ subunits, the N-terminal regions of which possess ligand-binding sites. The N terminus of all integrin ␣ subunits is composed of seven 60-aa repeats predicted to fold into a ␤-propeller structure (18) . In some integrins, including the four ␤2 integrins, a structurally characterized inserted (I) domain (19) of Ϸ200 residues exists between repeats 2 and 3, positioned on top of the ␤-propeller (18) . In LFA-1 (␣L␤2), the I domain has been shown to directly mediate conformation-and cation-dependent ICAM-1-binding through its metal ion-dependent adhesion site (20) (21) (22) (23) .
ICAM-1 has been shown to exist as a dimer and larger multimers on the cell surface, and dimerization appears to enhance binding to LFA-1 (24, 25) . Indeed, LFA-1-expressing lymphoblasts bind to cells expressing wild-type ICAM-1, which is largely dimeric, more efficiently than cells expressing an equal amount of glycosylphosphatidylinositol-linked ICAM-1, which is largely monomeric (24) . Recombinant soluble ICAM-1 (sICAM-1), lacking the transmembrane and cytoplasmic domains, exists as a monomer in solution (26, 27) . Engineered dimerization of sICAM-1 leads to significantly enhanced binding to LFA-1 compared with monomeric sICAM-1 (24, 28, 29) .
The overall topology of the ICAM-1 dimer on the cell surface has not yet been fully defined. However, data suggest that D5 and͞or the transmembrane domain are important for dimerization (24, 25) . Additionally, an x-ray crystal structure of ICAM-1 domains 1-2 revealed a hydrophobic dimerization interface in domain 1 on the ␤-sheet containing ␤-strands B, E, and D, suggesting this domain may also mediate dimerization (30) . Indeed, we have recently provided experimental evidence confirming that such a domain 1 dimerization interface exists in solution (C.-D.J., C.V.C., S. D. Redick, and M.S., unpublished results). Significantly, the ligandbinding surface for LFA-1 in the dimeric ICAM-1 crystal structure was found on the face of domain 1 opposite the dimerization interface (30) . The ligand-binding site is centered on Glu-34 (E34), which is the single most important residue for ligand binding and is hypothesized to ligate the Mg 2ϩ in the metal ion-dependent adhesion site of the I domain. E34 is located near the middle of the domain in ␤-strand C, on the edge of the ␤-sandwich. In the domain 1 dimer, the two E34 residues point away from one another and are separated by Ϸ42 Å (30) . With this geometry, simultaneous binding of two LFA-1 molecules seemed plausible. However, it would also be possible for a single molecule of LFA-1 to bind across the dimer interface and contact residues in both monomers. For example, E34 in one monomer is only 20 Å away from residue L43 in the other monomer.
Given the proximity of the dimerization interface and the LFA-1-binding interface in domain 1 of ICAM-1, we propose two basic models for the greater LFA-1 binding observed to dimeric ICAM-1 (Fig. 1A) . In model 1, all of the ICAM-1 contacts of LFA-1 occur within a single monomer, centered around E34. In this model, the increased binding of the dimer is derived from increased avidity, which by definition includes binding of two LFA-1 molecules to a single ICAM-1 dimer. In model 2, LFA-1 binds to the ICAM-1 dimer through both contacts centered around E34 of one monomer and contacts across the dimer interface to the second monomer ( Fig. 1 A,  model 2 ). In this model, the dimer represents a complete or ''fully competent'' LFA-1-binding surface, whereas the monomer contains only a partial LFA-1-binding surface.
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To differentiate between these mechanisms, we have created sICAM-1 constructs C-terminally fused to ACID and BASE ␣-helical coiled-coil peptides to drive the formation of specific ICAM-1 ACID-BASE coiled-coil heterodimers (Fig. 1B) . We have designed ICAM-1 heterodimers in which one of the LFA-1-binding sites was disrupted by mutation of E34 or completely deleted. Functional tests on these heterodimers clearly demonstrate that a monomer of ICAM-1 bears a complete set of LFA-1-binding determinants.
Methods
Cells and Antibodies. JY (Epstein-Barr virus-transfected B-cell), SKW3 (T cell lymphoma), 293T, and Chinese hamster ovary (CHO)-K1 cell lines were maintained as previously described (31) (32) (33) . CHO-K1 cells were maintained in Ham's F12K medium supplemented with 2 mM L-glutamine, 10% FBS, and 50 g͞m penicillin͞streptomycin. Peripheral blood T cells were prepared as described (34) . ICAM-1 mAbs R6.5 (35) , CA-7 (27), CL203 (36) , and CBRIC1͞11 (37) , and the LFA-1 blocking mAb TS1͞22 (38) have been described. Within ICAM-1, mAb R6.5 maps to domain 2 (26) , mAb CBRIC1͞11 maps to domain 3 (37) , mAb CL203 maps to domain 4 (26) , and mAb CA-7 maps to domain 5 (27) . mAb 2H11 was a generous gift from Ellis L. Reinherz (Dana-Faber Institute, Boston) (39) .
cDNA Constructions. The human wild-type ICAM-1 cDNA (40) was subcloned into the HindIII and NotI restriction sites of pAprM8 vector to generate ICAM-1͞pAprM8. A DNA construct encoding IgSF domains 1-5 of ICAM-1 fused to the ACID-p1 peptide (sICAM-1ACID) was prepared by using a three-round PCR protocol. In the first PCR reaction, by using ICAM-1͞pAprM8 as a template, an Ϸ260-bp fragment was generated that spanned from an internal ICAM-1 BglII site through codons for the last amino acids of the ICAM-1 ectodomain (SPRYE) fused with the first amino acids (AQCEKELQALEKENAQLE) of the ACID-p1 sequence. Also, by using the ICAM-1͞pAprM8 as a template, an Ϸ500-bp fragment was generated, beginning with a short sequence encoding the last C-terminal amino acids (KENAQLEWELQALEKELAQ) of the ACID-p1 sequence followed by a stop codon, Ϸ470 bp of nontranslated sequence, and a NotI site. In the final PCR reaction, the 260-and Ϸ500-bp products were used together as an overlapping template to generate an Ϸ760-bp product. After digestion with BglII and NotI, this product was used to replace the respective wild-type sequence in ICAM1͞pAprM8, generating sICAM-1ACID͞pAprM8. By using a similar cloning strategy, a DNA construct encoding the ICAM-1 ectodomain fused to the ␣-helical BASE-p1 peptide (sICAM-1 BASE) was prepared. The final amino acid sequences of the ACID-p1 and BASE-p1 peptides in sICAM-1ACID and sICAM-1BASE, respectively, were as follows: ACID-p1:
AQCEKELQALEKENAQLEWELQALEKELAQ; BASE-p1: AQCKKKLQALKKKNAQLKWKLQALKKKLAQ (41) . By using sICAM-1 ACID͞pAprM8 and sICAM-1 BASE͞ pAprM8 as templates, site-directed mutagenesis was performed to mutate E34 to lysine(K) resulting in sICAM-1 E34K ACID͞pAprM8 and sICAM-1 E34K BASE͞pAprM8. For the plasmid encoding only domains 3-5 of ICAM-1 fused to the BASE-p1 peptide (sICAM-1 ⌬D1-2 BASE͞pAprM8), domains 1 and 2 of ICAM-1 (184 residues) were deleted by using a long (45-bp) mutant oligonucleotide such that codons for the end of the signal sequence and F185 would be joined. Wild-type and mutant sICAM-1 BASE chimeras were further subcloned into the BamHI and NotI sites of pEF1͞V5 puro vector, whereas wild-type and mutant sICAM-1 ACID constructs were subcloned into the SpeI and NotI sites of pEF1͞V5 neo vector (Invitrogen).
cDNA Transfections. Transient transfection of 293T cells was performed as described (33) . CHO-K1 cells that stably express sICAM-1 ACID͞BASE heterodimers were generated by FUGENE 6 (Boehringer Mannheim) transfection of sICAM-1 ACID and BASE constructs followed by selection with, and maintenance in, 3 g͞ml of puromycin and 1 g͞ml neomycin beginning at 48 h. Labeled cell culture supernantants (500 l) were incubated with R6.5-, 2H11-, or CA-7-Sepharose beads (50 l of a 1:1 slurry coupled at 3 mg͞ml) for 3 h at 4°C. The immunoprecipitates were subjected to SDS͞10% PAGE and fluorography. Protein Purification. ICAM-1 heterodimers were purified at 4°C. Culture supernatants containing sICAM-1ACID and BASE proteins were passed through a 2H11 mAb affinity column (20 ml coupled at 2 mg͞ml), followed by extensive washing with 10 mM Tris⅐HCl, pH 8.0͞0.15 M NaCl. Bound proteins were eluted with 50 mM triethylamine, pH 11.5͞0.15 M NaCl and fractions were collected in test tubes containing 1͞10 volume 1 M Tris⅐HCl, pH 6.5. Pooled fractions were then subjected to Superdex 200 size exclusion chromatography in PBS (0.15 M NaCl͞2.7 mM KCl͞1.47 mM KH 2 PO 4 ͞4.86 mM Na 2 HPO 4 , pH 7.4) to remove aggregated materials. Monomeric sICAM-1 lacking the transmembrane and cytoplasmic domains was purchased from Boehringer Mannheim. Fc-ICAM-1, Fc-ICAM-2, and Fc-ICAM-3 chimeric proteins were purchased from R & D Systems.
Cell-Binding Assay. 2H11 mAb (50 l of 20 g͞ml in PBS) was adsorbed to each well of flat-bottom 96-well polystyrene plates (Flow Laboratories) by incubation overnight at 4°C. Nonspecific binding sites were blocked with 1% heat-treated BSA for 1 h at 37°C. Purified ICAM-1 heterodimers (50 l of a range of concentrations from 1.25 to 320 nM) were then incubated for 3 h at 37°C to allow binding to immobilized 2H11 mAb. The ICAM-1 density was determined by saturation binding with [ 125 I]-CBRIC1͞11 mAb, as described (31) . BCECF-AM-labeled cells (43) were resuspended (1 ϫ 10 6 cells͞ml) in L15 medium supplemented with 5% FBS (L15͞FBS). Fifty microliters of cell suspension was added to ICAM-1-coated wells with an equal volume of L15͞FBS containing phorbol 12-myristate 13-acetate (PMA) (100 ng͞ml). In some experiments, L15͞FBS and PMA were substituted with Hepesbuffered saline (20 mM Hepes, pH 7.5͞140 mM NaCl) supplemented with 2 mg͞ml of glucose and indicated cations or cation chelators. The 96-well plates were centrifuged at 200 ϫ g for 2 min at 4°C and incubated at 37°C for 30 min. Unbound cells were then removed by using a Microplate Autowasher (Bio-Tek Instruments, Winooski, VT). The fluorescence signal of bound cells (after washing) was expressed as a percentage of the fluorescence of total input cells (before washing) as quantitated on a fluorescent concentration analyzer (IDEXX, Westbrook, ME). The washing procedure was programmed (43) such that binding of mock-transfected cells or binding in the presence of ICAM-1-blocking mAb was below 5% of total input. Antibody-Binding Assay. mAbs R6.5, CA-7, or 2H11 (50 l of 10 g͞ml PBS) were adsorbed to each well of flat-bottom 96-well polystyrene plates (Flow Laboratories) by incubation overnight at 4°C. Nonspecific binding sites were blocked with 1% heattreated BSA for 1 h at 37°C. sICAM-1 or ICAM-1 heterodimers (E34͞E34 and E34͞⌬D1-D2) (500 ng͞ml in PBS) were then added to the wells and incubated for 30 min at 37°C followed by washing 3 ϫ with PBS. Binding of ICAM-1 was detected by incubation with biotin-conjugated CBRIC1͞11 mAb followed by washing with PBS and addition of streptavidin-conjugated horseradish peroxidase and 2,2Ј-azinobis[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt as substrate. 
Results

Expression of ICAM-1 ACID͞BASE Heterodimers.
To produce soluble ICAM-1 heterodimers, the transmembrane and cytoplasmic domains of ICAM-1 were replaced with peptides termed ''ACID'' and ''BASE'' that form ␣-helical coiled coils, with a strong preference for ACID-BASE heterodimers (39, 41) (Fig. 1B) . Cysteines were introduced in the ''d'' position of the first heptad repeat to covalently link the coiled coils (44) . Proteins from metabolically labeled 293T cells expressing sICAM-1ACID, sICAM-1BASE, or sICAM-1ACID and sICAM-1BASE together were immunoprecipitated with the ICAM-1-specific mAb R6.5 and subjected to SDS͞PAGE and fluorography ( Fig. 2A) . Disulfide-linked dimers were formed, as shown by SDS͞PAGE under nonreducing conditions (Fig. 2 A, lanes 2-4 compared with 6-8) . Cells doubly transfected with sICAM-1ACID and sICAM-1BASE formed dimers, as expected (Fig. 2 A, lanes 4 and 11) . Dimers were also formed by cells transfected with sICAM-1ACID alone and Material from CHO-K1 cells expressing E34͞E34, E34͞K34, E34͞⌬D1-D2, or K34͞K34 ICAM-1 heterodimers was purified with a 2H11 mAb column, subjected to SDS͞10% PAGE in the absence (lanes 1-4) and presence (lanes 5-8) of 10 mM DTT, and stained with Coomassie blue. (C) Purified ICAM-1 preparations (500 ng͞ml) were tested for binding to immobilized R6.5, CA7, or 2H11 mAb. Bound ICAM-1 was detected with biotin-conjugated-CBRIC1͞11 mAb followed by streptavidin-conjugated horseradish peroxidase and ELISA.
sICAM-1BASE alone (Fig. 2 A, lanes 2, 3, 9, and 10) ; however, the ratio of dimers to monomers was markedly higher for cells coexpressing sICAM-1ACID and sICAMBASE (Fig. 2 A, lanes 4 and  11) . The mAb 2H11 specifically recognizes the heterodimeric, coiled-coil state of the ACID-p1 and BASE-p1 peptides (39) . Immunoprecipitation with 2H11 mAb demonstrated that ACID͞BASE ␣-helical coiled-coil heterodimers were, indeed, formed by coexpression of the sICAM-1ACID and sICAM-1BASE chimeras (Fig. 2 A, lane 14) . Furthermore, mAb 2H11 did not immunoprecipitate material from cells expressing sICAM-1ACID or sICAM-1BASE alone (Fig. 2 A, lanes 12 and  13) , demonstrating that ACID͞BASE heterodimers could be isolated from ACID and BASE homodimers.
Stable transfectants of CHO-K1 cells were established that expressed sICAM-1 ACID͞sICAM-1 BASE (E34͞E34), sICAM-1ACID͞sICAM-1E34KBASE (E34͞K34), sICAM-1 ACID͞sICAM-1 ⌬D1-2 BASE (E34͞⌬D1-2), and sICAM-1E34K ACID͞sICAM-1 E34K BASE (K34͞K34) (Fig. 1B) . Heterodimers were specifically isolated by immunoaffinity chromatography with the 2H11 mAb specific for ACID͞BASE ␣-helical coiled-coil heterodimers. E34͞E34, E34͞K34 and K34͞K34 all migrated as dimers of Ϸ160 kDa on nonreducing SDS͞PAGE (Fig.  2B, lanes 2-4) and as monomers of 80 kDa on reducing SDS͞ PAGE (Fig. 2B, lanes 6-8) . E34͞⌬D1-2 ran as a single band of 135 kDa under nonreducing SDS͞PAGE (Fig. 2B, lane 1) , and as two bands of 80 and 55 kDa on reduction (Fig. 2B, lane 5) . As expected after isolation with 2H11 mAb affinity chromatography, homodimer bands of 160 and 110 kDa were absent from the E34͞ ⌬D1-2 preparation (Fig. 2B, lane 1) .
The mAb CA-7 has previously been shown to recognize D5 of ICAM-1 (27) in monomeric ICAM-1, while recognizing native cell surface-expressed dimeric ICAM-1 relatively poorly (24) . Thus, to confirm appropriate formation of ICAM-1 heterodimers, we assessed binding of mAbs CA-7, R6.5, and 2H11 to immobilized ICAM-1. R6.5 to domain 2 of ICAM-1 recognized sICAM-1, E34͞E34 and E34͞⌬D1-2 proteins similarly, and 2H11 bound E34͞E34 and E34͞⌬D1-2 similarly, but failed to bind sICAM-1 (Fig. 2C) . By contrast, CA-7 bound monomeric sICAM-1 efficiently but bound heterodimeric ICAM-1 (E34͞E34 and E34͞⌬D1-2) relatively weakly (Fig. 2C) . Thus, the soluble ICAM-1 heterodimers resembled cell surface ICAM-1 in masking of the CA-7 epitope. We further compared immunoprecipitation of monomeric and dimeric forms of ICAM-1 by CA-7 mAb (Fig. 2 A, lanes 15-17) . Compared with R6.5 mAb (Fig. 2 A, lanes 9-11) , CA-7 mAb precipitated similar amounts of monomer (80% as much as R6.5 mAb), but markedly lesser amounts of dimer (25% as much as R6.5 mAb). Therefore, the differential CA-7 binding to dimers likely reflects proper dimer formation, as opposed to masking of the CA-7 epitope by ACID and BASE peptides.
Binding of LFA-1-Bearing Cells to Immobilized ICAM-1 Heterodimers.
To assess function, ICAM-1 heterodimers were immobilized on 2H11-coated 96-well plates and assessed for their ability to support PMA-stimulated adhesion of JY B lymphoblastoid cells, SKW3 T lymphoma cells, and resting peripheral blood T cells. A range of heterodimer concentrations was used, and the density of captured ICAM-1 was determined by saturation binding with 125 I-CBRIC1͞11 mAb. Binding of all three cell types depended on LFA-1 and ICAM-1, as shown by Ն97% inhibition with mAbs TS1͞22 and RR1͞1, respectively. The E34͞E34, E34͞K34, and E34͞⌬D1-2 dimers all supported binding that depended on their density on the substrate (Fig. 3) . By contrast, the K34͞K34 dimer was completely inactive for all three cell types. The ability of the E34͞K34 and E34͞⌬D1-D2 dimers to support LFA-1-dependent adhesion was reduced compared with the E34͞E34 dimer (Fig. 3) . Maximal binding was similar; however, a 2-fold higher density of dimer was required for half-maximal binding to E34͞K34 and E34͞⌬D1-D2 compared with E34͞E34. Similar results were obtained when SKW3 cell binding was stimulated by either Mn 2ϩ (Fig. 4A) or Mg 2ϩ ͞EGTA (Fig. 4B ) rather than PMA, or when binding was in the presence of Mg 2ϩ (Fig. 4B) . In all cases, a 2-fold higher density of E34͞K34 than E34͞E34 was required to support the same amount of adhesion. PMA and Mn 2ϩ or Mg 2ϩ ͞EGTA have been reported to stimulate LFA-1-dependent binding to ICAM-1 by avidity and affinity modulation, respectively (45) . Because binding to E34͞K34 and E34͞⌬D1-D2 is equivalent, and because dimerization of domain 1 is precluded in E34͞⌬D1-D2, these data demonstrate that an individual monomer of ICAM-1 possesses all of the necessary LFA-1-binding determinants. 
Interaction of ICAM-1 Heterodimers with the Open LFA-1 I Domain in
BIAcore. To more directly characterize the ligand-binding properties of the ICAM-1 heterodimers, we performed BIAcore studies in which ICAM-1 proteins were immobilized on the surface of a BIAcore sensor chip. Binding of a purified soluble I domain mutant that is locked in the open conformation by introduction of two cysteines that form a conformation-selective disulfide bond (22, 23) was measured. In initial experiments, specificity was demonstrated in that the open LFA-1 I domain exhibited cation-dependent binding to chips with immobilized sICAM-1 but not to chips with immobilized BSA (data not shown). Kinetics were measured for binding of the open LFA-1 I domain to monomeric sICAM-1 and heterodimeric E34͞E34, E34͞K34 and E34͞⌬D1-D2 ICAM-1 (Table 1) . Whereas K34͞K34 exhibited very weak binding affinity (K D Ϸ 0.5 mM), sICAM-1, E34͞E34, E34͞K34, and E34͞⌬D1-D2 all bound the open LFA-1 I domain with high affinity and strikingly similar k on , k off and K D values ( Table 1 ). The K D values ranged from 167 to 181 nM. These data are consistent with the cell-binding experiments shown in Figs. 3 and 4 , and demonstrate that LFA-1 binds to individual ICAM-1 monomers independently of dimerization state.
Discussion
Many previous studies have shown that dimeric ICAM-1 is more effective than momeric ICAM-1 as a ligand for LFA-1 (24, 25, 28, 29) . The LFA-1-binding site is located entirely within domain 1 of ICAM-1 (26, 46) . Given the finding that ICAM-1 dimerizes through an interface in domain 1 (ref. 30 ; C.-D.J., C.V.C., S. D. Redick, and M.S., unpublished results), we hypothesized two possible mechanisms for the enhanced LFA-1-binding activity of dimeric ICAM-1 (Fig. 1 A) . Fundamentally, these models differ in the question of whether LFA-1 recognizes an individual monomer as a complete binding surface or if it requires additional binding determinants, supplied by the second monomer of a dimer, for optimal binding. By creating ICAM-1 heterodimers of defined composition, where one of the two LFA-1-binding sites was either disrupted or completely deleted, we have established that all of the LFA-1-binding determinants exist within domain 1 of a single ICAM-1 monomer. In other words, the binding site does not extend across a dimer interface.
To assay adhesion through LFA-1, equal amounts of ICAM-1 heterodimers were immobilized and binding of LFA-1-bearing cells was assessed. The heterodimers were presented in a uniform manner on the substrate by capture with a mAb to the ACID͞ BASE ␣-helical coiled coil. Because the heterodimers were not free in solution but immobilized on a surface, monovalency or bivalency of the dimers per se was irrelevant. Rather the avidity of the LFA-1-bearing cells for the ICAM-1 bound surface, a function of the total number of intact, ''fully competent'' binding sites present in the cell͞substrate contact region, was important. We found that the E34͞E34 dimer exhibited Ϸ2-fold greater cell-binding efficiency than the E34͞K34 dimer, an equal amount of which contains only half the number of active LFA-1-binding sites. Significantly, binding of cells to E34͞⌬D1-2, in which dimerization of domain 1 is precluded, was not further reduced compared with E34͞K34, demonstrating that LFA-1 binding is not enhanced by or dependent on an ability to form a domain 1 dimerization interface. Furthermore, these results demonstrate that dimerization of ICAM-1 does not enhance adhesiveness, because the dimers that contained only These data suggest that the previously reported higher effectiveness of the soluble ICAM-1 dimer is likely because of its bivalency. It is noteworthy that most previous studies of dimeric ICAM-1 function have been performed with soluble ICAM-1 binding to an LFA-1-bearing surface (24, 25, 28, 29) . In solution, the bivalent nature of an ICAM-1 dimer will cause a significant suppression of k off yielding a greater overall affinity. Indeed, we have previously demonstrated this for ICAM-1 dimer binding to rhinovirus (47) and have confirmed it for ICAM-1 dimer binding to the immobilized open LFA-1 I domain (data not shown).
Although this finding is clearly relevant to the design of antiintegrin-based therapies, it raises the question what, then, is the physiological role of ICAM-1 dimerization on the cell surface? In fact, functional advantages of dimerization have been observed with cell-surface ICAM-1 (Ϸ2-fold increased adhesion to dimer compared with monomer), although more modest than those seen for soluble ICAM-1 dimers (10-to 100-fold increased binding of dimer compared with monomer) (24, 25, 28, 29) . However, on the cell surface, native dimeric ICAM-1 was compared with monomeric ICAM-1 with an artificial glycosylphosphatidyl inositol membrane anchor. Binding of the CA-7 mAb was greatly enhanced to the glycosylphosphatidyl inositol anchored ICAM-1, suggesting that a putative dimerization interface in domain 5 was unmasked. The ICAM-1 dimers studied here, including those containing only one active LFA-1-binding site per dimer, demonstrated a masking of the CA-7 epitope similar to that seen for cell surface dimers. The epitope was not masked in monomers fused to the ␣-helical peptides, suggesting that dimerization at domain 5, and not fusion to the ␣-helical peptide, resulted in masking. Therefore, the orientational influence of dimerization in the C-terminal portion of ICAM-1 is retained in the molecules containing one and two binding sites for LFA-1 in this study, but not in the study of Miller et al. (24) . In the present study, we have ruled out an effect of dimerization on the nature of the LFA-1-binding site in domain 1 of ICAM-1. Moreover, we have demonstrated that when present on a surface and at the same density of total active binding sites, dimers that contain a single LFA-1-binding site are as effective as dimers that contain two binding sites. Thus, one likely functional role for ICAM-1 dimerization on the cell surface as demonstrated by Miller et al. (24) is to properly orient ICAM-1 and present it for binding to LFA-1. Putative dimerization sites at the C terminus and in domain 5 appear sufficient for this orienting function, because we observed no difference in efficacy when the domain 1 dimerization site was eliminated in the E34͞⌬D1-2 heterodimer. Another possible role for dimerization is in signaling through ICAM-1 (15, 16) .
Overall, the observations presented here demonstrate that each individual ICAM-1 monomer is fully competent to bind LFA-1 and that ICAM-1 dimerization, although functionally important for orientation on the cell surface, is not required to form a complete LFA-1-binding site.
